Our Pipeline
Santa Ana is focused on the discovery and development of precision therapeutics for autoimmune and inflammatory diseases. Leveraging deep experience in discovering and developing proprietary antibodies, we are advancing a portfolio of highly selective and optimized therapeutics for broad populations of patients with high unmet need.
SAB01 is a highly selective, long-acting, novel bispecific antibody designed for best-in-class mast cell depletion with enhanced safety. Utilizing a precision approach, the bispecific targets c-kit and a unique anchor target, restricting depletion to mast cells without the unwanted off-mast cell tolerability and safety concerns shown by current clinical approaches. We intend to develop SAB01 in a broad range of mast cell driven disorders such as urticarias, prurigo nodularis, eosinophilic esophagitis, food allergy and others. SAB01 is currently in IND-enabling studies.
SAB03 is a novel, highly potent PD-1 monoclonal antibody designed to aggressively modulate T cells to elicit a disease modifying effect. SAB03 uniquely depletes and suppresses PD-1 high, medium and low expressing autoreactive T cells, thereby addressing the full range of pathogenic antigen-reactive T cells for potentially deeper and more durable clinical response. SAB03 is currently in IND-enabling studies.
SAB05 is a novel glucocorticoid-antibody conjugate designed for enhanced efficacy with expansive therapeutic utility, designed to harness the well-established therapeutic benefit of glucocorticoids without their significant liabilities. SAB05 was specifically engineered with multiple distinct mechanisms of action to drive efficacy at local sites of inflammation while simultaneously avoiding the safety issues associated with the use of systemic glucocorticoids. SAB05 is in late lead optimization.
SAB06 is a long-acting, novel bispecific that leverages two distinct and clinically derisked pathways. Combining multiple mechanisms action, SAB06 offers potential break through efficacy over current clinical approaches, allowing for better disease control in IBD, Crohn’s disease, and other gastrointestinal diseases. SAB06 is in lead optimization.